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CIMPIn recent years, attention has focused on the biology and potential clinical importance of the CpG island
methylator phenotype (CIMP) in colorectal cancer (CRC). While it is generally well accepted that etiologically
and clinically distinct subgroups exist in this disease, a precise definition of CIMP remains to be established.
Here, we summarize existing literature that documents the prevalence of CIMP in CRC, with particular atten-
tion to the various methods and definitions used to classify a tumor as CIMP positive. Through a systematic
review on both case-series and population based studies, we examined only original research articles report-
ing on sporadic CRC and/or adenomas in unselected cases. Forty-eight papers published between January
1999 and August 2011 met the inclusion criteria. We describe the use of multiple gene panels, marker thresh-
old values, and laboratory techniques which results in a wide range in the prevalence of CIMP. Because there
is no universal standard or consensus on quantifying the phenotype, establishing its true prevalence is a chal-
lenge. This bottleneck is becoming increasingly evident as molecular pathological epidemiology continues to
offer possibilities for clear answers regarding environmental risk factors and disease trends. For the first time,
large, unselected series of cases are available for analysis, but comparing populations and pooling data will
remain a challenge unless a universal definition of CIMP and a consensus on analysis can be reached, and
the primary cause of CIMP identified.
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It is argued that genetics supersedes epigenetics in CRC and
methylation is a consequence of aging, not neoplasia [53].
It is suggested that CIMP is a statistical artifact [49].
The suggestion that methylation is primarily a consequence of
aging and not neoplasia is refuted [10].
The biological relevance of CIMP is confirmed in a large
population based sample [44].
The need for a consensus on how to define and analyze CIMP is
identified [10].
Weisenberger panel shown to be specific and sensitive for CIMP-
high tumors in population based sample [46].
Distinct features of CIMP tumors are characterized [51,52].
The term CIMP is coined to describe CRC tumors with a high
degree of promoter hypermethylation [30].
A robust 5 gene panel for CIMP is introduced which shows
correlations with BRAF mutation and MSI [11].
Quantitative MSP (MethyLight) technology introduced for CIMP
analyses [11].
Population based sample suggests three subgroups are needed to
define CIMP adequately [43].
Lack of consensus guidelines on definition of CIMP.
MethyLight technology is introduced [50].
Time
Fig. 1. A timeline of the major developments surrounding CIMP over the past decade
[10,11,30,43,44,46,49,50–53].
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Altered epigenetic regulation of gene expression in cancer is orga-
nized at multiple levels and involves DNA methylation, histone modifi-
cations, chromatin remodeling and non-coding RNAs [1]. Such
modifications are of interest to cancer prevention, detection and man-
agement strategies because they can be present in pre-cancerous ‘nor-
mal’ tissue, thereby modifying cancer risk [2–4], and are associated
with both cancer initiation and progression [3,5,6]. Furthermore, it is
becoming clear that epigenetic aberrations are promising molecular
markers for early detection and markers of prognosis and response to
therapy [7–9].
The most studied epigenetic alteration is DNA hypermethylation of
promoter-associated CpG islands of tumor suppressor and DNA repair
genes, which is now recognized as a common feature of human neopla-
sia as it leads to transcriptional silencing of the gene [10]. Widespread
CpG island promoter methylation, also referred to as the CpG island
methylator phenotype (CIMP) [10–13], has been reported in several
tumor types, including gastric [14–19], lung [20,21], liver [22], ovarian
[23], glioblastomas [24], endometrial [25,26], breast [27] and leukemias
[28,29]. However, the termwas first coined [30] and the phenotype has
been most studied in colorectal cancer (CRC).
CRC tumors characterized by CIMP are thought to arise via the ser-
rated neoplasia pathway [31], and have distinctly different histology
when compared to tumors derived from traditional adenoma-
carcinoma pathway [32–35]. An early event in CIMP tumors appears
to be a mutation in the BRAF proto-oncogene, which inhibits normal
apoptosis of colonic epithelial cells [34]. In addition, most CIMP
CRCs are characterized by promoter CpG island methylation of the
mismatch repair gene, MLH1, resulting in its transcriptional inactiva-
tion. Loss of MLH1 is thought to cause microsatellite instability (MSI),
a form of genetic instability characterized by length alterations within
simple repeated microsatellite sequences of DNA [36,37]. Once MLH1
is inactivated, the rate of progression to malignant transformation is
rapid [34]. Clinically, there is evidence to suggest that CIMP is associ-
ated with prognosis [38,39] and it is also being investigated as a pre-
dictive marker for response to chemotherapy treatment [40–42].
Descriptively, tumors of the serrated neoplasia pathway are associat-
ed with older age, female sex, and tumors of the proximal colon
[11,43–47]. Furthermore, CIMP has been investigated in association
with a number of environmental risk factors as was recently reviewed
by Curtin et al. [48].
Although it has been more than a decade since CIMP was first
identified in CRC, the path to accepting these tumors as an etiological-
ly and clinically distinct group of the disease has not been without
controversy (Fig. 1), and to date, the cause of CIMP remains unknown.
Moreover, there is no gold standard with respect to gene panels,
marker thresholds or techniques for detection of the altered DNA
methylation used to define this phenotype. Here, we systematically
review the literature to provide a synopsis of current knowledge on
CIMP in CRC research, shedding light on the need for universal con-
sensus guidelines.
2. Methods
2.1. Criteria for inclusion
Articles eligible for this review were studies that reported on the
prevalence of CIMP in sporadic CRC and/or colorectal adenomas. Fur-
thermore, only original articles (i.e. not reviews or editorials) that
consisted of unselected cases were considered.
2.2. Search strategies
A systematic review was performed for all English language arti-
cles until June 2011 in three databases: MEDLINE, PUBMED, andEMBASE. The keywords used were combined uniformly and exten-
sively in each database and included: adenocarcinoma; cancer; carci-
noma; cimp; colon; colonic; rectum; rectal; colorectal; cpg island
methylation phenotype; cpg island methylator phenotype; neoplasia;
neoplasm. The articles identified by the search were registered in an
Endnote database without duplicates. Articles were first selected or
excluded based on title. Then, abstracts and full text of articles were
reviewed for the inclusion criteria. This scheme is outlined in Fig. 2.
2.3. Assessment of validity and data extraction
Two authors (LH and CK) independently screened all retrieved re-
ports and selected those that were potentially valid. The discrepan-
cies of validity assessment were resolved by discussion with MvE.
Information was sought for the following four criteria: method used
to detect CIMP, gene panel used to define CIMP, threshold for CIMP
positivity, and CIMP prevalence. An electronic, standardized registra-
tion form was used for data extraction from the selected articles and
640 potentially relevant papers identified and
retrieved  in PUBMED, EMBASE and
MEDLINE databases
 420 papers excluded because the
title/abstract clearly reflected that the
paper was not original research, did not
involve CRC or did not report on CIMP
220 articles screened further by reading the main
text
 172 excluded based on main text:
- 87  papers involved a duplicate
population
- 30 papers had no definition of
CIMP clear and/or prevalence
of CIMP not reported
- 22 papers discussed irrelevant
subject matter
- 16  contained preselected cases
- 9 papers were not original
research
- 7 papers focused only on
familial CRC/Lynch Syndrome
- 1 study  had a main body
written in Japanese
38 CRC papers included in review
10 Adenoma papers included in review
 (1 paper included both carcinomas and
adenomas)
48 papers in total included in review
Fig. 2. Flow diagram of study selection process.
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population, study size, study design, methods, CIMP panel used,
threshold for CIMP positivity, CIMP prevalence.
3. Results
3.1. Search results
Searching the PUBMED, EMBASE and MEDLINE databases initially
yielded a total of 754 citations. After excluding duplicates, 640 articles
remained, and 420 were discarded on the basis of a title clearly not
reflecting the inclusion criteria (not an original article, not involving
sporadic CRC, not reporting on CIMP). Of the remaining 220 articles,
172 were further discarded after reading the main text (87 papers in-
cluded a duplicate study population; 30 papers contained no clear
definition of CIMP and/or the prevalence of CIMP was not reported;
22 papers discussed methylation, but not CIMP; 16 papers described
pre-selected cases (i.e. tumors characterized by MSI or BRAF muta-
tion); 9 papers were not original research; 7 papers described familial
CRC or Lynch Syndrome cases; and 1 paper had a main body written
in Japanese). Thus, 48 publications from January 1999–August 2011
were ultimately included in this review. These included 38 papers
reporting on sporadic CRC cases, and 10 papers reporting on colorec-
tal adenomas, and 1 paper described both adenomas and carcinomas.
3.2. Description of studies
The characteristics of included studies are summarized in Table 1.
The 38 publications on sporadic CRC came from 15 different coun-
tries, and included 26 case series, 3 population based series, 2 articles
reporting case–cohort data (one study population; colon and rectumwere reported separately [54,55]), and 6 articles reporting prospec-
tive cohort data (from 5 populations; one population reports on 2 dif-
ferent gene panels [13,46]). One paper also reported population
based case-series and prospective cohort data in the same paper
[38]. With respect to studies involving case series, 5 different labora-
tory techniques were used to quantify CIMP, 12 different gene panels
were used to define CIMP, and marker thresholds varied depending
on, and also within, gene panels. With respect to population based
studies, 3 different methods and 4 different gene panels were utilized
to define CIMP. The 11 publications on colorectal adenomas spanned
4 countries and were all case series. Two different laboratory tech-
niques and 5 different gene panels were used to define CIMP.
Many different combinations of gene panel/marker thresholds/
laboratory methods were used to quantify CIMP, and furthermore, it
is difficult to give a range of the prevalence of CIMP, because the var-
iation in observed prevalence is partly dependent on characteristics
known to be associated with CIMP, such as location (i.e. studies
only reporting only on colon tumors will likely have a higher preva-
lence of CIMP than studies reporting on both colon and rectum
tumors). In general, we observed no clear patterns indicating that
specific gene panels and/or laboratory technique gave consistently a
higher or lower CIMP prevalence.3.3. Gene panels and marker thresholds
The so-called ‘classic panel’, which includes MINT1, MINT2,
MINT31, CDKN2A (p16) and MLH1, was identified by a PCR-based
analysis of SmaI digestion sites and has been used since then [10].
In 2006, a robust five gene panel was introduced by Weisenberger
et al. [11], which includes the genes CACNA1G, IGF2, NEUROG1,
RUNX3 and SOCS1. This panel was identified by unsupervised
Table 1
Summary of studies of CIMP detection and status.
Study characteristics Assessment of CIMP




Sporadic CRC Proximal Distalg Overall
Case series
An et al., 2010 [62] Japan 94 Colorectal Classic panelc Bisulfite pyrosequencing ≥2/5 methylated 43 17 28

















Frazier et al., 2003 [64] USA 47 Colorectal Classic panel MSP ≥3/5 methylated –h – 45
Lee et al., 2008 [65] South Korea 134 Colorectal Classic panel MSP ≥2/5 methylated 44 23 31
Suehiro et al., 2008 [66] USA
Hong Kong





O'Brien et al. 2006 [67] USA 10 (SC)f
59 (TCA)
























Karpinski et al., 2010 [69] Poland 186 Colorectal Weisenberger panel MSP ≥3/5 methylated – – 25
Ang et al., 2010 [70] Australia 91 Colorectal Weisenberger panel MethyLight (PMR=4)e ≥3/5 methylated – – 18
Greco et al., 2010 [71] Australia 55 Colorectal Weisenberger panel MethyLight (PMR=10) ≥3/5 methylated – – 26
Iacopetta et al., 2007 [72] Australia 205 Colon Weisenberger panel MethyLight (PMR=10) ≥3/5 methylated 85 15 17
Kawakami et al., 2008
[73]
Japan 150 Colorectal Weisenberger panel MethyLight (PMR=10) ≥3/5 methylated – – 9
Sanchez et al., 2009 [74] USA 391 Colorectal Weisenberger panel MethyLight (PMR=10) ≥3/5 methylated 89 11 21
Weisenberger et al. 2006
[11]
Australia 187 Colorectal Weisenberger panel MethyLight (PMR=10) ≥3/5 methylated 67 33 18
Cheng et al. 2008 [75] USA 161 Colon Weisenberger panel MethyLight (PMR=10) ≥3/5 methylated – – 20
Hinoue et al. 2011 [59] Netherlands 125 Colorectal Weisenberger panel MethyLight (PMR=10) ≥3/5 methylated 86 15 22
Kim et al., 2009 [76] South Korea 320 Colorectal Weisenberger panel+CDKN2A (p16), CRABP1,
MLH1
MethyLight (PMR=4) ≥5/8 methylated 76 – 12
Arain et al. 2010 [77] USA 167 Colon MINT1, MINT2, MINT31, P16INK4, MGMT, MLH1 Real Time PCR ≥3/6 methylated 58 42 38
Goel et al., 2007 [60] Canada, Germany
USA
Japan
126 Colon MINT1, MINT2, MINT31, p16INK4, MGMT, MLH1 MSP ≥3/6 methylated – – 31
Cai et al., 2008 [78] China 69 Colon p14ARF, MLH1, p16INK4, MGMT, MINT1 MSP ≥3/5 methylated – – 18
Deng et al., 2008 [79] USA 74 Colorectal MLH1, p16ink4A, HIC1, RASSF2, MINT1, MINT31 +
SFRP1, SFRP2, SFRP4, SFRP5 +













Kakar et al., 2008 [80] USA 83 Colorectal MLH1, p16, HIC1, RASSF2, ID4, MINT1, MINT31 MSP ≥3/7 methylated – – 34
Kambara et al., 2004 [81] Australia 145 Colorectal MINT1, MINT2, MINT12, and MINT31 COBRA ≥3/4 methylated – – 25
Kim et al. [82] South Korea 285 Colorectal MLH1, MINT1, MINT2, MINT31, p16INK4a, p14ARF,
CACNA1G
Bisulfite Pyrosequencing ≥2/7 methylated – – 36
Sugai et al., 2006 [83] Japan 119 Colorectal MINT1, MINT2, MINT31, p14, p16, MGMT, MLH1,
RASSF-1A
MSP ≥3/8 methylated 51 25 32
Toyota et al., 1999 [30] USA 41 MLH1, MINT1, MINT2, MINT12, MINT31 and p16 MSP ≥3/6 methylated 82 37 51
Ahn et al. 2011 [61] South Korea 161 Colon MINT1, MINT2, MINT31, hMLH1, p16, p14, and
WNT5A
Bisulfide pyrosequencing ≥3/7 methylated – – 18
Population based series
Samowitz et al., 2005
[44]

















Barault et al., 2008 [43] France 582 Colon Classic panel MSP ≥4/5 methylated 81 19 17
Jover et al., 2010 [84] Spain 320 Colorectal Weisenberger panel Bisulfite pyrosequencing ≥3/5 methylated – – 30
Dahlin et al., 2010 [38] Sweden 414 Colorectal Weisenberger panel+CDKN2A (p16), CRABP1,
MLH1
MethyLight (PMR=4) ≥6/8 methylated 76 24 11
Case control
Samowitz et al., 2006
[54]
USA 1143 cases Colon Classic panel MSP ≥2/5 methylated 74 23 29
Slattery et al., 2010 [55] USA 750 cases Rectum Classic panel MSP ≥2/5 methylated – – 11
Prospective cohort
de Vogel et al., 2008 [85] Netherlands 120,852 (cases=734) Colorectal Weisenberger panel MSP ≥3/5 methylated – – 27
English et al., 2008 [86] Australia 41,328 (cases=717) Colorectal Weisenberger panel MethyLight (PMR=10) ≥3/5 methylated 84 15 14
Limsui et al., 2010 [87] USA 37, 399 (cases=555)
women only
Colorectal Weisenberger panel MethyLight (PMR=10) ≥3/5 methylated – – 31
Ogino et al., 2006 [13] USA 173,229 (cases=460) Colorectal CACNA1G, CDKN2A (p16), CRABP1, MLH1, NEUROG1 MethyLight (PMR=4) ≥4/5 methylated – – 17
Ogino et al., 2007 [46] USA 173,229 (cases=920) Colorectal Weisenberger panel+CDKN2A (p16), CRABP1,
MLH1
MethyLight (PMR=4) ≥6/8 methylated – – 15
Dahlin et al., 2010 [38] Sweden 166,414 (cases=190) Colorectal Weisenberger panel+CDKN2A (p16), CRABP1,
MLH1
MethyLight (PMR=4) ≥6/8 methylated 78 22 14
Adenomasf
Case series
Chan et al., 2002 [88] USA 102 (HP)
8 (SA)
19 (TA)









O'Brien et al., 2004 [89] USA 79 (HP) Colorectal Classic Panel MSP ≥2/5 methylated 80 23 51
Yang et al., 2004 [90] USA 79 (HP)
25 (SA)






Hiraoka et al., 2006 [91] Japan 205 Colorectal Classic Panel MSP ≥2/5 methylated 57 43 22
























Park et al., 2003 [92] USA 22 (SSA)
34 (TA)
Colorectal Classic Panel MSP ≥2/5 methylated 70 64 68
18
Vaughn et al., 2010 [93] USA 52 (HP) Proximal
Colon
Weisenberger Panel MethyLight (PMR=10) ≥3/5 methylated 48 4 29
Velho et al., 2008 [94] Portugal 17 (HP) Colorectal Weisenberger Panel MSP ≥3/5 methylated – − 25
Rashid et al., 2001 [95] USA 50 Colorectal p16, MINT2, MINT31 MSP ≥2/3 methylated 23 29 25
Kim et al., 2005 [96] South Korea 40 Colorectal APC, THBS1, MGMT, MLH1, GSTP1 MSP ≥2/5 methylated 42 58 30
















a Gene names are reported as they were in the original study.
b CIMP-H refers to either CIMP or in the instance that a study reported three CIMP categories, CIMP-high.
c Classic panel includes the genes: MINT1, MINT2, MINT31, CDKN2A(p16) and hMLH1.
d Weisenberger panel includes the genes: CACA1G, IGF2, NEUROG1, RUNX3 and SOCS1.
e PMR = percentage of methylated reference.
f HP (hyperplastic polyps), SA (serrated adenoma), TA (traditional adenoma), GCSP (goblet cell serrated polyp), MVSP (microvesicular serrated polyp), SPAP (serrated polyp with abnormal proliferation), sTA (small traditional adenoma),
lTA (large traditional adenoma), SC (serrated carcinomas), TCA (traditional carcinomas).
g Some studies only reported distal colon, whereas others reported distal location (distal colon+rectum).
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specific CpG sites of 295 CRCs and independently confirmed the exis-
tence of CIMP as well as showed the association between CIMP and
BRAF mutation. It has now been shown that MINT1, MINT2, and
MINT31 are not specific for BRAF-mutated CIMP tumors [11]. Howev-
er, studies validating the Weisenberger markers [46,56] emphasized
that such findings do not indicate that these MINT markers or other
CpG islands are inappropriate for assessment of CIMP in CRC; there
is a possibility that a difference in primer designs and PCR conditions
may substantially change sensitivity and specificity of a particular
marker for the detection of CIMP [46]. Most recently, Ogino et al. pro-
posed that a panel of (at least) four markers including RUNX3, CAC-
NA1G, IGF2, and MLH1 should constitute a sensitive and specific
CIMP panel for the purpose of research and clinical use [46], but it is
unknown how many studies have adapted this advice. At present,
no set criteria for defining an ideal panel of CIMP markers exists,
and one may argue which criteria are most important to consider;
i.e. strength of association with BRAF mutation, proximal location in
the tumor vs. tumor specific methylation. Ultimately, genome-wide
studies of methylation and hierarchical cluster analysis of the data
may eventually reveal a distinct subgroup of CRC with very frequent
methylation of functionally important tumor suppressor genes, from
which a small panel could then be chosen.
Furthermore, there is debate whether CIMP should be distin-
guished as two categories (‘CIMP’ and ‘non-CIMP’) [11,30], three cat-
egories (either ‘CIMP-high, CIMP low, CIMP-0’ [57] or ‘CIMP1, CIMP2,
CIMP-negative [58]), or most recently, four categories (CIMP-high,
CIMP-low and two clusters of non-CIMP depending on the frequency
of TP53mutation) [59]. This stems from the observation that some tu-
mors demonstrate an intermediate amount of aberrant DNA or a clus-
ter with differentially methylated genes than the classical CIMP
cluster. Recently, Kaneda et al. [3] reported that a two panel method
utilizing two different sets of CIMP-related markers is required to
properly classify CRC into one of three DNA methylation epigen-
otypes: high, intermediate and low.
In practice, two prospective cohort studies report similar preva-
lence using an 8 gene panel to distinguish the three categories pro-
posed by Ogino et al. (the five genes in the Weisenberger panel plus
CDKN2A (p16), CRABP, and MLH1) [38,46]. However, it was also
reported that differences between CIMP-low (1/8 to 5/8 methylated
promoters) and non-CIMP (0/8 methylated promoters) were not
large [46].3.4. Analytical methods
From Table 1, it is clear that a number of methods can be used to
detect promoter hypermethylation in tumors, including methylation
specific PCR (MSP), real-time PCR (such as MethyLight) and bisulfite
pyrosequencing. It has been suggested that a quantitative analysis,
for example MethyLight, is needed for studying methylation [10,13],
however, qualitative MSP has been shown to be effective and specific
and does not require specific equipment [43,60]. Even though Methy-
Light is quantitative, there is a chance that data can differ from study
to study, depending on what value is set as the ‘percentage of methyl-
ated reference’ (PMR) and the percentage of tumor cells present in
the sample. The PMR is the value at which a given loci is declared
methylated; some studies report using a PMR of >10 to declare meth-
ylation, whereas other report using a lower PMR of >4. However, it is
also important to note that not all studies specifically report this
value. A higher PMR results in a stricter definition of methylation,
and consequently, a stricter definition of CIMP. Bisulfite pyrosequen-
cing quantitatively measures the methylation status of several CpG
sites in a given sequence, allowing the mean percentage of methyl-
ation of detected sites to be determined as a representative value
[61].4. Discussion
From this systematic review of the literature, it is clear that nu-
merous methods and definitions are being utilized to quantify CIMP
in CRC tumors. Although some of this heterogeneity may be explained
by time (i.e. there have been advances in technology that have
allowed for the discovery of new gene panels since CIMP was first
identified), the fact remains that unlike other molecular endpoints
of CRC, such as MSI, no clear biological cause or standard definition
exists for defining CIMP. This makes determining the true prevalence
of CIMP and comparing results across studies a challenge, and leads to
other important questions. Which gene panels, marker thresholds
and laboratory methods are ‘best’ for identifying CIMP, or does it
even matter?
With respect to gene panels and marker thresholds, additional
studies are necessary to assess whether CIMP-low represents a dis-
tinct phenotype in CRC, and, the debate surrounding this will likely
continue until a biological cause for CIMP has been determined. In a
recent review, Curtin et al. [48] conclude that BRAF and KRAS onco-
gene mutation status will help refine the definition of CIMP as it
evolves, as it is becoming increasingly common to define the patho-
logical and clinical features of CRC when classifying tumors, and a
number of studies have shown highly methylated tumors correlate
with BRAF mutations whereas intermediate and low methylated tu-
mors correlate more highly with KRAS mutations [3,58,70,98].
It is difficult to conclude whether the difference in CIMP preva-
lence between studies arises because of a difference in methods, or
a difference in choice of primers and/or location of methylation in
the markers. MSP has a high detection signal, and subsequently, a
higher prevalence of CIMP will be observed with this technique.
Also, the primer/probe location of analyzed CpG nucleotides may dif-
fer between studies, and although most studies analyze methylation
“around the transcription start site”, no standard protocol for where
to look for methylation exists. Promoter CpG islands of genes have
often been reported as ‘unmethylated’ or ‘hypermethylated’, based
on data of only a small number of CpG dinucleotides independent of
location or the assays which have been used. It is now known that
the location of core regions and the density of methylation required
for gene silencing can vary per gene, therefore, a broader view than
just the classical dogma of promoter CpG island methylation and
gene silencing is needed to interpret data on DNA methylation, gene
expression and clinico-pathological associations [99]. In the future,
this may be accomplished by novel technologies that enable (semi)
epigenome wide analyses of methylation profiles for specific genes.
The lack of consensus on how to quantify CIMP is a major problem.
However, the biggest knowledge deficit facing this field of research is
that the biological cause of CIMP in CRC remains unknown. One hy-
pothesis is that CIMP occurs as a result of underlying genetic defects.
In a recent review, Grady describes that this may include activating
mutations in DNAmethyltransferases or alterations in genes that con-
trol mechanisms that protect DNA from aberrant methylation [100]. It
is also plausible that genetic and epigenetic abnormalities simulta-
neously contribute to tumor formation and progression [10,100].
Strong correlations observed between tumors with a high degree of
promoter methylation and BRAF, and between tumors with an inter-
mediate/low degree of methylation and KRAS also supports that
there is causal link between methylation epigenotypes and oncogene
mutation [3,58,70,98].
An alternative model gaining attention is that CIMP reflects chronic
exposure to epimutagens that could then cause or accelerate cancer de-
velopment through epigenetic pathways [10,100]. For the first time,
large, population based studies offer a unique opportunity to elucidate
such associations and link lifestyle and exposures to the phenotype.
Molecular pathological epidemiology [101] now offers an opportunity
to analyze environmental risk factors and disease trends in large num-
bers of unselected cases. With respect to CIMP, associations between
83L.A.E. Hughes et al. / Biochimica et Biophysica Acta 1825 (2012) 77–85anthropometry and physical activity [55,102,103], smoking [54,87], al-
cohol [103,104], childhood energy restriction [105], dietary folate
[103,106,107], and ethnicity [86] have been reported in case–control
and prospective cohort studies. Findings from these studies offer in-
sights on the potential etiology of CIMP in CRC. For instance, English
et al. [86] reported that people of southern European origin had
lower risk of colorectal cancers with CIMP than people of Anglo-Celtic
origin, which may in part be due to genetic factors that are less com-
mon in people of southern European origin. Differences in ethnicity
may explain why the prevalence of CIMP differs between study popu-
lations, even if the same gene panel and analytic methods were used in
each. We have reported in the Netherlands Cohort Study that those ex-
posed to severe caloric restriction early in life have a low risk of colo-
rectal cancers with CIMP [105]. This builds on the hypothesis that
methylation is an early event in CRC progression [45], and that expo-
sures long before a given CRC event may already have implications
for disease risk later in life. Such a hypothesis is supported by studies
that have examined methylation patterns in normal tissue. For in-
stance, it has been observed that CpG methylation in normal colorectal
mucosa is related to advancing age [72,108–110], sex [108], race [72],
rectal location [72,109], red blood cell (RBC) folate levels [109] and
smoking [110]. The opportunity to pool data from large population
based studies in order to improve the precision of risk estimates is a
key motivation to work toward a universal definition of CIMP.
It is evident that a universal definition of CIMP is far from estab-
lished and until the biological cause of CIMP is determined, this may
remain a challenge. However, in order to take full advantage of the
potentials of molecular pathological epidemiology, as well as develop
the potential of methylation-based diagnostics and treatments for
CRC, it is becoming urgent to generate discussion on this topic and
aim for a consensus. To assess which technique, marker panel and
threshold defines CIMP best, it will be necessary for several popula-
tion based studies to test multiple techniques, maker panels and
thresholds within their own set of samples.
Acknowledgments
We would like to honor the memory of Dr. Minoru Toyota, a
wonderful colleague and friend, who was the first to identify CIMP
and continued to study this phenotype and other epigenetic altera-
tions in gastrointestinal malignancies.
This research was performed within the framework of CTMM,
the Center for Translational Molecular Medicine, project DeCoDe
(grant 03O-101).
References
[1] P.W. Laird, Cancer epigenetics, Hum. Mol. Genet. 1 (2005) R65–R76.
[2] A. Kaneda, A.P. Feinberg, Loss of imprinting of IGF2: a common epigenetic
modifier of intestinal tumor risk, Cancer Res. 65 (2005) 11236–11240.
[3] A. Kaneda, K. Yagi, Two groups of DNAmethylation markers to classify colorectal
cancer into three epigenotypes, Cancer Sci. 102 (2011) 18–24.
[4] T. Sakatani, A. Kaneda, C.A. Iacobuzio-Donahue, et al., Loss of imprinting of Igf2
alters intestinal maturation and tumorigenesis in mice, Science 307 (2005)
1976–1978.
[5] S.B. Baylin, J.E. Ohm, Epigenetic gene silencing in cancer—a mechanism for early
oncogenic pathway addiction? Nat. Rev. Cancer 6 (2006) 107–116.
[6] A.P. Feinberg, R. Ohlsson, S. Henikoff, The epigenetic progenitor origin of human
cancer, Nat. Rev. Genet. 7 (2006) 21–33.
[7] P.W. Laird, The power and the promise of DNA methylation markers, Nat. Rev.
Cancer 3 (2003) 253–266.
[8] M. van Engeland, S. Derks, K.M. Smits, et al., Colorectal cancer epigenetics:
complex simplicity, J. Clin. Oncol. 29 (2011) 1382–1391.
[9] M. Esteller, Epigenetics in cancer, N. Engl. J. Med. 358 (2008) 1148–1159.
[10] J.P. Issa, CpG island methylator phenotype in cancer, Nat. Rev. Cancer 4 (2004)
988–993.
[11] D.J. Weisenberger, K.D. Siegmund, M. Campan, et al., CpG island methylator
phenotype underlies sporadic microsatellite instability and is tightly associated
with BRAF mutation in colorectal cancer, Nat. Genet. 38 (2006) 787–793.
[12] J.J. Wong, N.J. Hawkins, R.L. Ward, Colorectal cancer: a model for epigenetic
tumorigenesis, Gut 56 (2007) 140–148.[13] S. Ogino, M. Cantor, T. Kawasaki, et al., CpG island methylator phenotype (CIMP)
of colorectal cancer is best characterised by quantitative DNA methylation
analysis and prospective cohort studies, Gut 55 (2006) 1000–1006.
[14] C. An, I.S. Choi, J.C. Yao, et al., Prognostic significance of CpG island methylator
phenotype and microsatellite instability in gastric carcinoma, Clin. Cancer Res.
11 (2005) 656–663.
[15] T. Etoh, Y. Kanai, S. Ushijima, et al., Increased DNAmethyltransferase 1 (DNMT1)
protein expression correlates significantly with poorer tumor differentiation
and frequent DNA hypermethylation of multiple CpG islands in gastric cancers,
Am. J. Pathol. 164 (2004) 689–699.
[16] H. Kim, Y.H. Kim, S.E. Kim, et al., Concerted promoter hypermethylation of
hMLH1, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite
instability, J. Pathol. 200 (2003) 23–31.
[17] M. Kusano, M. Toyota, H. Suzuki, et al., Genetic, epigenetic, and clinicopathologic
features of gastric carcinomas with the CpG island methylator phenotype and an
association with Epstein–Barr virus, Cancer 106 (2006) 1467–1479.
[18] N. Oue, Y. Oshimo, H. Nakayama, et al., DNA methylation of multiple genes in
gastric carcinoma: association with histological type and CpG island methylator
phenotype, Cancer Sci. 94 (2003) 901–905.
[19] M. Toyota, N. Ahuja, H. Suzuki, et al., Aberrant methylation in gastric cancer
associated with the CpG island methylator phenotype, Cancer Res. 59 (1999)
5438–5442.
[20] C.J. Marsit, E.A. Houseman, B.C. Christensen, et al., Examination of a CpG island
methylator phenotype and implications of methylation profiles in solid tumors,
Cancer Res. 66 (2006) 10621–10629.
[21] M. Suzuki, H. Shigematsu, T. Iizasa, et al., Exclusive mutation in epidermal
growth factor receptor gene, HER-2, and KRAS, and synchronous methylation
of nonsmall cell lung cancer, Cancer 106 (2006) 2200–2207.
[22] L. Shen, N. Ahuja, Y. Shen, et al., DNA methylation and environmental exposures
in human hepatocellular carcinoma, J. Natl. Cancer Inst. 94 (2002) 755–761.
[23] G. Strathdee, K. Appleton, M. Illand, et al., Primary ovarian carcinomas display
multiple methylator phenotypes involving known tumor suppressor genes,
Am. J. Pathol. 158 (2001) 1121–1127.
[24] Q. Li, A. Jedlicka, N. Ahuja, et al., Concordant methylation of the ER and N33
genes in glioblastoma multiforme, Oncogene 16 (1998) 3197–3202.
[25] M. Sasaki, A. Dharia, B.R. Oh, et al., Progesterone receptor B gene inactivation
and CpG hypermethylation in human uterine endometrial cancer, Cancer Res.
61 (2001) 97–102.
[26] M. Sasaki, M. Kaneuchi, N. Sakuragi, et al., Multiple promoters of catechol-O-
methyltransferase gene are selectively inactivated by CpG hypermethylation in
endometrial cancer, Cancer Res. 63 (2003) 3101–3106.
[27] F. Fang, S. Turcan, A. Rimner, et al., Breast cancer methylomes establish an
epigenomic foundation for metastasis, Sci. Transl. Med. 3 (2011) 75ra25.
[28] G. Garcia-Manero, J. Daniel, T.L. Smith, et al., DNA methylation of multiple
promoter-associated CpG islands in adult acute lymphocytic leukemia, Clin.
Cancer Res. 8 (2002) 2217–2224.
[29] M. Toyota, K.J. Kopecky, M.O. Toyota, et al., Methylation profiling in acute
myeloid leukemia, Blood 97 (2001) 2823–2829.
[30] M. Toyota, N. Ahuja, M. Ohe-Toyota, et al., CpG island methylator phenotype in
colorectal cancer, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 8681–8686.
[31] A.E. Noffsinger, Serrated polyps and colorectal cancer: new pathway to malig-
nancy, Annu. Rev. Pathol. 4 (2009) 343–364.
[32] J.E. East, B.P. Saunders, J.R. Jass, Sporadic and syndromic hyperplastic polyps and
serrated adenomas of the colon: classification, molecular genetics, natural histo-
ry, and clinical management, Gastroenterol. Clin. North Am. 37 (2008) 25–46.
[33] D.C. Snover, Serrated polyps of the large intestine, Semin. Diagn. Pathol. 22
(2005) 301–308.
[34] D.C. Snover, Update on the serrated pathway to colorectal carcinoma, Hum.
Pathol. 42 (2011) 1–10.
[35] D.C. Snover, J.R. Jass, C. Fenoglio-Preiser, et al., Serrated polyps of the large intes-
tine: a morphologic and molecular review of an evolving concept, Am. J. Clin.
Pathol. 124 (2005) 380–391.
[36] K. Imai, H. Yamamoto, Carcinogenesis and microsatellite instability: the interre-
lationship between genetics and epigenetics, Carcinogenesis 29 (2008) 673–680.
[37] J.G. Herman, A. Umar, K. Polyak, et al., Incidence and functional consequences of
hMLH1 promoter hypermethylation in colorectal carcinoma, Proc. Natl. Acad.
Sci. U. S. A. 95 (1998) 6870–6875.
[38] A.M. Dahlin, R. Palmqvist, M.L. Henriksson, et al., The role of the CpG island
methylator phenotype in colorectal cancer prognosis depends on microsatellite
instability screening status, Clin. Cancer Res. 16 (2010) 1845–1855.
[39] S. Ogino, K. Nosho, G.J. Kirkner, et al., CpG island methylator phenotype, micro-
satellite instability, BRAF mutation and clinical outcome in colon cancer, Gut 58
(2009) 90–96.
[40] B. Iacopetta, K. Kawakami, T. Watanabe, Predicting clinical outcome of
5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island
methylator phenotype the 5-fluorouracil-responsive subgroup? Int. J. Clin.
Oncol. 13 (2008) 498–503.
[41] R. Jover, T.P. Nguyen, L. Perez-Carbonell, et al., 5-Fluorouracil adjuvant
chemotherapy does not increase survival in patients with CpG island methylator
phenotype colorectal cancer, Gastroenterology 140 (2011) 1174–1181.
[42] M. Van Rijnsoever, H. Elsaleh, D. Joseph, et al., CpG island methylator phenotype
is an independent predictor of survival benefit from 5-fluorouracil in stage III
colorectal cancer, Clin. Cancer Res. 9 (2003) 2898–2903.
[43] L. Barault, C. Charon-Barra, V. Jooste, et al., Hypermethylator phenotype in spo-
radic colon cancer: study on a population-based series of 582 cases, Cancer Res.
68 (2008) 8541–8846.
84 L.A.E. Hughes et al. / Biochimica et Biophysica Acta 1825 (2012) 77–85[44] W.S. Samowitz, H. Albertsen, J. Herrick, et al., Evaluation of a large, population-
based sample supports a CpG island methylator phenotype in colon cancer,
Gastroenterology 129 (2005) 837–845.
[45] J.R. Jass, Classification of colorectal cancer based on correlation of clinical,
morphological and molecular features, Histopathology 50 (2007) 113–130.
[46] S. Ogino, T. Kawasaki, G.J. Kirkner, et al., Evaluation of markers for CpG island
methylator phenotype (CIMP) in colorectal cancer by a large population-based
sample, J. Mol. Diagn. 9 (2007) 305–314.
[47] W.S. Samowitz, The CpG island methylator phenotype in colorectal cancer,
J. Mol. Diagn. 9 (2007) 281–283.
[48] K. Curtin, M.L. Slattery, W.S. Samowitz, CpG island methylation in colorectal
cancer: past, present and future, Pathol. Res. Int. (2011) 902674.
[49] C. Anacleto, A.M. Leopoldino, B. Rossi, et al., Colorectal cancer “methylator
phenotype”: fact or artifact? Neoplasia 7 (2005) 331–335.
[50] C.A. Eads, K.D. Danenberg, K. Kawakami, et al., MethyLight: a high-throughput
assay to measure DNA methylation, Nucleic Acids Res. 28 (2000) E32.
[51] M. Toyota, M. Ohe-Toyota, N. Ahuja, et al., Distinct genetic profiles in colorectal
tumors with or without the CpG island methylator phenotype, Proc. Natl. Acad.
Sci. U. S. A. 97 (2000) 710–715.
[52] M. van Rijnsoever, F. Grieu, H. Elsaleh, et al., Characterisation of colorectal cancers
showing hypermethylation at multiple CpG islands, Gut 51 (2002) 797–802.
[53] K. Yamashita, T. Dai, Y. Dai, et al., Genetics supersedes epigenetics in colon
cancer phenotype, Cancer Cell 4 (2003) 121–131.
[54] W.S. Samowitz, H. Albertsen, C. Sweeney, et al., Association of smoking, CpG
island methylator phenotype, and V600E BRAF mutations in colon cancer,
J. Natl. Cancer Inst. 98 (2006) 1731–1738.
[55] M.L. Slattery, K. Curtin, R.K. Wolff, et al., Diet, physical activity, and body size
associations with rectal tumor mutations and epigenetic changes, Cancer Causes
Control 21 (2010) 1237–1245.
[56] K. Nosho, N. Irahara, K. Shima, et al., Comprehensive biostatistical analysis of CpG
island methylator phenotype in colorectal cancer using a large population-based
sample, PLoS One 3 (2008) e3698.
[57] S. Ogino, T. Kawasaki, G.J. Kirkner, et al., CpG island methylator phenotype-low
(CIMP-low) in colorectal cancer: possible associations with male sex and KRAS
mutations, J. Mol. Diagn. 8 (2006) 582–588.
[58] L. Shen, M. Toyota, Y. Kondo, et al., Integrated genetic and epigenetic
analysis identifies three different subclasses of colon cancer, Proc. Natl. Acad.
Sci. U. S. A. 104 (2007) 18654–18659.
[59] T. Hinoue, D.J. Weisenberger, C.P. Lange, et al., Genome-scale analysis of
aberrant DNA methylation in colorectal cancer, Genome Res. (2011), doi:
10.1101/gr.117523.11.
[60] A. Goel, T. Nagasaka, C.N. Arnold, et al., The CpG island methylator phenotype
and chromosomal instability are inversely correlated in sporadic colorectal can-
cer, Gastroenterology 132 (2007) 127–138.
[61] J.B. Ahn, W.B. Chung, O. Maeda, et al., DNAmethylation predicts recurrence from
resected stage III proximal colon cancer, Cancer 117 (2011) 1847–1854.
[62] B. An, Y. Kondo, Y. Okamoto, et al., Characteristic methylation profile in CpG
island methylator phenotype-negative distal colorectal cancers, Int. J. Cancer
127 (2010) 2095–2105.
[63] A.O. Chan, A.S. Soliman, Q. Zhang, et al., Differing DNA methylation patterns and
gene mutation frequencies in colorectal carcinomas from Middle Eastern coun-
tries, Clin. Cancer Res. 11 (2005) 8281–8287.
[64] M.L. Frazier, L. Xi, J. Zong, et al., Association of the CpG island methylator pheno-
type with family history of cancer in patients with colorectal cancer, Cancer Res.
63 (2003) 4805–4808.
[65] S. Lee, N.Y. Cho,M. Choi, et al., Clinicopathological features of CpG islandmethylator
phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/
BRAF mutation, Pathol. Int. 58 (2008) 104–113.
[66] Y. Suehiro, C.W. Wong, L.R. Chirieac, et al., Epigenetic–genetic interactions in the
APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma, Clin. Cancer Res.
14 (2008) 2560–2569.
[67] M.J. O'Brien, S. Yang, C. Mack, et al., Comparison of microsatellite instability, CpG
island methylation phenotype, BRAF and KRAS status in serrated polyps and tra-
ditional adenomas indicates separate pathways to distinct colorectal carcinoma
end points, Am. J. Surg. Pathol. 30 (2006) 1491–1501.
[68] S. Lee, N.Y. Cho, E.J. Yoo, et al., CpG island methylator phenotype in colorectal
cancers: comparison of the new and classic CpG island methylator phenotype
marker panels, Arch. Pathol. Lab. Med. 132 (2008) 1657–1665.
[69] P. Karpinski, A. Myszka, D. Ramsey, et al., Polymorphisms in methyl-group
metabolism genes and risk of sporadic colorectal cancer with relation to the
CpG island methylator phenotype, Cancer Epidemiol. 34 (2010) 338–344.
[70] P.W. Ang, M. Loh, N. Liem, et al., Comprehensive profiling of DNA methylation in
colorectal cancer reveals subgroups with distinct clinicopathological and molec-
ular features, BMC Cancer 10 (2010) 227–235.
[71] S.A. Greco, J. Chia, K.J. Inglis, et al., Thrombospondin-4 is a putative tumour-
suppressor gene in colorectal cancer that exhibits age-related methylation,
BMC Cancer 10 (2010) 494–504.
[72] B. Iacopetta, F. Grieu, M. Phillips, et al., Methylation levels of LINE-1 repeats and
CpG island loci are inversely related in normal colonic mucosa, Cancer Sci. 98
(2007) 1454–1460.
[73] K. Kawakami, A. Ooyama, A. Ruszkiewicz, et al., Low expression of gamma-
glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island
methylator phenotype, Br. J. Cancer 98 (2008) 1555–1561.
[74] J.A. Sanchez, L. Krumroy, S. Plummer, et al., Genetic and epigenetic classifica-
tions define clinical phenotypes and determine patient outcomes in colorectal
cancer, Br. J. Surg. 96 (2009) 1196–1204.[75] Y.W. Cheng, H. Pincas, M.D. Bacolod, et al., CpG island methylator phenotype
associates with low-degree chromosomal abnormalities in colorectal cancer,
Clin. Cancer Res. 14 (2008) 6005–6013.
[76] J.H. Kim, S.H. Shin, H.J. Kwon, et al., Prognostic implications of CpG island hyper-
methylator phenotype in colorectal cancers, Virchows Arch. 455 (2009)
485–494.
[77] M.A. Arain, M. Sawhney, S. Sheikh, et al., CIMP status of interval colon cancers:
another piece to the puzzle, Am. J. Gastroenterol. 105 (2010) 1189–1195.
[78] G. Cai, Y. Xu, H. Lu, et al., Clinicopathologic and molecular features of sporadic
microsatellite- and chromosomal-stable colorectal cancers, Int. J. Colorectal
Dis. 23 (2008) 365–373.
[79] G. Deng, S. Kakar, H. Tanaka, et al., Proximal and distal colorectal cancers
show distinct gene-specific methylation profiles and clinical and molecular
characteristics, Eur. J. Cancer 44 (2008) 1290–1301.
[80] S. Kakar, G. Deng, V. Sahai, et al., Clinicopathologic characteristics, CpG island
methylator phenotype, and BRAF mutations in microsatellite-stable colorectal
cancers without chromosomal instability, Arch. Pathol. Lab. Med. 132 (2008)
958–964.
[81] T. Kambara, L.A. Simms, V.L. Whitehall, et al., BRAF mutation is associated with
DNA methylation in serrated polyps and cancers of the colorectum, Gut 53
(2004) 1137–1144.
[82] J.C. Kim, J.S. Choi, S.A. Roh, et al., Promoter methylation of specific genes is asso-
ciated with the phenotype and progression of colorectal adenocarcinomas, Ann.
Surg. Oncol. 17 (2010) 1767–1776.
[83] T. Sugai, W. Habano, Y.F. Jiao, et al., Analysis of molecular alterations in left- and
right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis:
proposal for new molecular profile of colorectal carcinomas, J. Mol. Diagn.
8 (2006) 193–201.
[84] R. Jover, T.P. Nguyen, L. Perez-Carbonell, et al., 5-Fluorouracil adjuvant chemo-
therapy does not increase survival in patients with CpG island methylator
phenotype colorectal cancer, Gastroenterology 140 (2011) 1174–1181.
[85] S. de Vogel, K.A. Wouters, R.W. Godschalk, Genetic variants of methyl metaboliz-
ing enzymes and epigenetic regulators: associations with promoter CpG island
hypermethylation in colorectal cancer, Cancer Epidemiol. Biomarkers Prev. 18
(2009) 3086–3096.
[86] D.R. English, J.P. Young, J.A. Simpson, et al., Ethnicity and risk for colorectal
cancers showing somatic BRAF V600E mutation or CpG island methylator
phenotype, Cancer Epidemiol. Biomarkers Prev. 17 (2008) 1774–1780.
[87] D. Limsui, R.A. Vierkant, L.S. Tillmans, et al., Cigarette smoking and colorectal
cancer risk by molecularly defined subtypes, J. Natl. Cancer Inst. 102 (2010)
1012–1022.
[88] A.O. Chan, J.P. Issa, J.S. Morris, et al., Concordant CpG island methylation in
hyperplastic polyposis, Am. J. Pathol. 160 (2002) 529–536.
[89] M.J. O'Brien, S. Yang, J.L. Clebanoff, et al., Hyperplastic (serrated) polyps of
the colorectum: relationship of CpG islandmethylator phenotype andK-rasmutation
to location and histologic subtype, Am. J. Surg. Pathol. 28 (2004) 423–434.
[90] S. Yang, F.A. Farraye, C. Mack, et al., BRAF and KRAS Mutations in hyperplastic
polyps and serrated adenomas of the colorectum: relationship to histology
and CpG island methylation status, Am. J. Surg. Pathol. 28 (2004) 1452–1459.
[91] S. Hiraoka, J. Kato, M. Tatsukawa, et al., Laterally spreading type of colorectal
adenoma exhibits a unique methylation phenotype and K-ras mutations,
Gastroenterology 131 (2006) 379–389.
[92] S.J. Park, A. Rashid, J.H. Lee, et al., Frequent CpG island methylation in serrated
adenomas of the colorectum, Am. J. Pathol. 162 (2003) 815–822.
[93] C.P. Vaughn, A.R. Wilson, W.S. Samowitz, Quantitative evaluation of CpG island
methylation in hyperplastic polyps, Mod. Pathol. 23 (2010) 151–156.
[94] S. Velho, C. Moutinho, L. Cirnes, et al., BRAF, KRAS and PIK3CA mutations in colo-
rectal serrated polyps and cancer: primary or secondary genetic events in colorec-
tal carcinogenesis? BMC Cancer 8 (2008) 255–261.
[95] A. Rashid, L. Shen, J.S. Morris, et al., CpG island methylation in colorectal adeno-
mas, Am. J. Pathol. 159 (2001) 1129–1135.
[96] H.C. Kim, S.A. Roh, I.H. Ga, et al., CpG island methylation as an early event
during adenoma progression in carcinogenesis of sporadic colorectal cancer,
J. Gastroenterol. Hepatol. 20 (2005) 1920–1926.
[97] Y.H. Kim, S. Kakar, L. Cun, et al., Distinct CpG island methylation profiles and
BRAF mutation status in serrated and adenomatous colorectal polyps, Int. J. Can-
cer 123 (2008) 2587–2593.
[98] N. Tanaka, C. Huttenhower, K. Nosho, et al., Novel application of structural equa-
tion modeling to correlation structure analysis of CpG island methylation in
colorectal cancer, Am. J. Pathol. 177 (2010) 2731–2740.
[99] I.J. van Vlodrop, H.E. Niessen, S. Derks, et al., Analysis of promoter CpG island
hypermethylation in cancer: location, location, location! Clin. Cancer Res. 17
(2011) 4225–4231.
[100] W.M. Grady, CIMP and colon cancer gets more complicated, Gut 56 (2007)
1498–1500.
[101] S. Ogino, A.T. Chan, C.S. Fuchs, et al., Molecular pathological epidemiology of
colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field,
Gut 60 (2010) 397–411.
[102] L.A. Hughes, C.C. Simons, P.A. van den Brandt, et al., Body size, physical activity
and risk of colorectal cancer with or without the CpG island methylator pheno-
type (CIMP), PLoS One 6 (2011) e18571.
[103] M.L. Slattery, K. Curtin, C. Sweeney, et al., Diet and lifestyle factor associations
with CpG island methylator phenotype and BRAF mutations in colon cancer,
Int. J. Cancer 120 (2007) 656–663.
[104] M.L. Slattery, R.K. Wolff, J.S. Herrick, et al., Alcohol consumption and rectal tumor
mutations and epigenetic changes, Dis. Colon Rectum 53 (2010) 1182–1189.
85L.A.E. Hughes et al. / Biochimica et Biophysica Acta 1825 (2012) 77–85[105] L.A.Hughes, P.A. vandenBrandt, A.P. de Bruine, et al., Early life exposure to famine and
colorectal cancer risk: a role for epigenetic mechanisms, PLoS One 4 (2009) e7951.
[106] S. de Vogel, K.A. Wouters, R.W. Gottschalk, et al., Genetic variants of methyl
metabolizing enzymes and epigenetic regulators: associations with promoter
CpG island hypermethylation in colorectal cancer, Cancer Epidemiol. Bio-
markers Prev. 18 (2009) 3086–3096.
[107] B. Van Guelpen, A.M. Dahlin, J. Hultdin, et al., One-carbon metabolism and CpG
island methylator phenotype status in incident colorectal cancer: a nested
case-referent study, Cancer Causes Control 21 (2011) 557–566.[108] K. Kawakami, A. Ruszkiewicz, G. Bennett, et al., DNA hypermethylation in
the normal colonic mucosa of patients with colorectal cancer, Br. J. Cancer 94
(2006) 593–598.
[109] K. Wallace, M.V. Grau, A.J. Levine, Association between folate levels and CpG
Island hypermethylation in normal colorectal mucosa, Cancer Prev. Res. 3
(2010) 1552–1564.
[110] B.C. Paun, D. Kukuruga, Z. Jin, Relation between normal rectal methylation,
smoking status, and the presence or absence of colorectal adenomas, Cancer
116 (2010) 4495–4501.
